Company intelligence / Profile preview

Yuzi Holdings

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

M701 (EpCAM/CD3 BsAb) in Phase II for malignant ascites (MA) and pleural effusion (MPE); Y101D in Phase Ib/II for solid tumors and pancreatic cancer; Y332 in Phase I dose-escalation for solid tumors; Y400 rights transferred.

Therapeutic areas: OncologyOphthalmology
Modalities: Bispecific monoclonal antibody
Industry: Biotech

Partnerships

CSPC Pharmaceutical Group (stakeholder)Shenzhen Kangzhe Vision and SOTER BIOPHARMA (Y400 rights transfer)CMS Vision (Y400 asset transfer)

Beyond the preview

Go deeper on Yuzi Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuzi Holdings.

Explore the full profile